FierceBiotech 21 mai 2026 ASCO: Merck, Kelun's sac-TMT ADC combo beats Keytruda by 65% on progression in first-line lung cancer
FierceBiotech 21 mai 2026 Lilly’s triple-G drug helps patients lose roughly a quarter of weight, showcasing competitive profile
FierceBiotech 21 mai 2026 Infex, following in Insmed’s footsteps, advances lung disease candidate after clearing phase 2a
FierceBiotech 20 mai 2026 US taps small San Diego biotech for experimental Ebola treatment as epidemic worsens
FierceBiotech 20 mai 2026 GHO Capital, CBC Group plan to merge, forming $21B healthcare investment firm
FierceBiotech 20 mai 2026 With $30M launch, Oorja Bio breathes new life into South Korean fibrosis candidate
FierceBiotech 20 mai 2026 Lilly pens $202M deal for preclinical DNA delivery biotech Engage as M&A streak continues
FierceBiotech 20 mai 2026 BMS taps Anthropic’s Claude for enterprise-wide AI adoption to speed R&D, global workflows
FierceBiotech 20 mai 2026 Immunovant pays out $39M to call time on FcRn inhibitor after eye disease phase 3 fails
FierceBiotech 20 mai 2026 Parabilis, fresh from inking Regeneron pact, plans IPO to fund tumor drug’s phase 3 push
FierceBiotech 20 mai 2026 Pfizer furthers pneumococcal efforts, remains ‘comfortable’ taking on emerging threats: vaccine chief